HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $289
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $243 to $289.
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $243 to $289.